BioRestorative Therapies, Inc.
BRTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. Valued at $8.2M, BRTX is a micro-cap name in its sector. The company develops programs related to the treatment of disc/spine disease and metabolic disorders.
Market Cap
$8.2M
Beta
0.64
P/E (TTM)
—
P/E (Fwd)
-0.62
EPS (TTM)
$-1.05
EPS (Fwd)
$-0.52
ROE
-241.1%
ROA
-118.8%
Cash
$3.6M
Total Debt
$28,774
Free CF
-$9.7M
52W Change
-80.6%
Annual Financials
Cash vs Debt
Where BRTX stands vs its 150-day and 200-day moving averages
As of the July 14, 2026 close, BRTX finished 37.04% below its 150-day moving average ($0.54) and 55.26% below its 200-day moving average ($0.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BRTX overbought or oversold?
At the July 14, 2026 close, BRTX's RSI(14) was 27.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.6M in cash comfortably exceeding the $29K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$9.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -241.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $120K (2022) to $360K (2025), reflecting a 200% increase over the period.
With a beta below 0.7, BioRestorative Therapies, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, BRTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioRestorative Therapies, Inc. and its sector.